Cachexia

It is usually associated with chronic disease, and in the supplied literature it is especially discussed in the setting of advanced cancer. Cancer-related cachexia is linked to tumor- and treatment-related factors, and inflammatory mediators such as IL-6 family cytokines are implicated in its development. Excess parathyroid hormone-related protein from malignant cancer cells is also described as a contributor to protein-energy wasting and cachexia.

The syndrome involves progressive wasting of skeletal muscle and adipose tissue together with systemic inflammation and other metabolic abnormalities. In cancer cachexia, inflammatory cytokines including IL-6, leukemia inhibitory factor, and oncostatin M promote lipolysis and proteolysis through JAK/STAT3 signaling. The literature also links cachexia with anorexia, asthenia, and sarcopenia, reflecting overlapping pathways of weakness, appetite loss, and muscle loss.

Chronic disease is the broad risk context supported by the grounding. In oncology, advanced cancer and tumor- and treatment-related factors are associated with malnutrition/cachexia/sarcopenia, and the condition is reported across different cancer types and settings. The supplied material also notes that inflammatory cytokine activity and malignant production of PTHrP are associated with cachexia.

In cancer cachexia, management is described at the level of nutritional, pharmacologic, and other interventions such as exercise. Dietary counseling, with or without oral nutritional supplements, may increase body weight in some trials, and pharmacologic interventions have been associated with improvements in appetite and/or body weight. The grounding supports a multimodal supportive-care approach rather than a single definitive therapy.